Therapeutic approaches in treating Creutzfeldt-Jakob disease - What does the future hold?

Expert Opinion on Pharmacotherapy

Volumn 5, Issue 11, 2004, Pages 2391-2396

  Croes, Esther A ^a,b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b NONE   (Netherlands)

Author keywords

CJD; Creutzfeldt Jakob disease; Pharmacotherapeutics; Prion

Indexed keywords

ACRIDINE; AMPHOTERICIN B; ANTHRACYCLINE DERIVATIVE; CHLORPROMAZINE; CONGO RED; MEPACRINE; PENTOSAN POLYSULFATE; PEPTIDE DERIVATIVE; PHENOTHIAZINE DERIVATIVE; POLYANION; PRION PROTEIN; PROTEIN ANTIBODY; PYRROLE DERIVATIVE; TETRACYCLINE DERIVATIVE;

ANTICHOLINERGIC EFFECT; ANXIETY DISORDER; BETA SHEET; BITTER TASTE; CREUTZFELDT JAKOB DISEASE; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE TRANSMISSION; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; EXTRAPYRAMIDAL SYNDROME; EYE DISEASE; GASTROINTESTINAL MOTILITY; GENE MUTATION; HEADACHE; HEMATOLOGIC DISEASE; HUMAN; NAIL DISEASE; NAUSEA; NEUROPATHOLOGY; NONHUMAN; PREVALENCE; PRION DISEASE; RESPIRATION DEPRESSION; RETROSPECTIVE STUDY; REVIEW; SEDATION; SKIN DISCOLORATION; SOMNOLENCE; TASTE DISORDER;

ANIMALS; ANTIBODIES; CREUTZFELDT-JAKOB SYNDROME; HUMANS; PEPTIDE FRAGMENTS; PRIONS; PROTEIN STRUCTURE, SECONDARY;

EID: 8544232789     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.5.11.2391     Document Type: Review

References (50)

1. PRUSINER SB: Prions. Proc. Natl. Acad. Sci. USA (1998) 95:13363-13383.
2. PAN KM, BALDWIN M, NGUYEN J et al. Conversion of α-helices into β-sheet features in the formation of the scrapie prion protein. Proc. Natl. Acad. Sci. USA (1993) 90:10962-10966.
3. PRUSINER SB, SCOTT M, FOSTER D et al.: Transgenetic studies implicate interaction between homologous PrP isoforms in scrapie prion replication. Cell (1990) 63:673-686.
4. BORCHELT DR, TARABOULOS A, PRUSINER SB: Evidence for synthesis of scrapie prion proteins in the endocytic pathway. J. Biol. Chem. (1992) 267:16188-16199.
5. TARABOULOS A, SERBAN D, PRUSINER SB: Scrapie prion proteins accumulate in the cytoplasm of persistently infected cultured cells. J. Cell Biol. (1990) 110:2117-2132.
6. TARABOULOS A, SCOTT M, SEMENOV A, LASZLO L, PRUSINER SB: Cholesterol depletion and modification of COOH-terminal targeting sequence of the prion protein inhibits formation of the scrapie isoform. J. Cell Biol. (1995) 129:121-132.
7. KANEKO K, VEY M, SCOTT M, PILKUHN S, COHEN FE, PRUSINER SB: COOH-terminal sequence of the cellular prion protein directs subcellular trafficking and controls conversion into the scrapie isoform. Proc. Natl. Acad. Sci. USA (1997) 94:2333-2338.
8. PRUSINER SB, HSIAO KK: Human prion diseases. Ann. Neurol. (1994) 35:385-395.
9. WILL RG, ALPEROVITCH A, POSER S et al.: Descriptive epidemiology of Creutzfeldt-Jakob disease in six European countries, 1993-1995. EU Collaborative Study Group for CJD. Ann. Neurol. (1998) 43:763-767.
10. WILL RG, IRONSIDE JW, ZEIDLER M et al.: A new variant of Creutzfeldt-Jakob disease in the UK. Lancet (1996) 347 921-925.
11. HILL AF, DESBRUSLAIS M, JOINER S et al.: The same prion strain causes vCJD and BSE. Nature (1997) 389:448-450, 526.
12. BRUCE ME, WILL RG, IRONSIDE JW et al.: Transmissions to mice indicate that 'new variant' CJD is caused by the BSE agent. Nature (1997) 389:498-501.
13. BROWN P, PREECE M, BRANDEL JP et al.: Iatrogenic Creutzfeldt-Jakob disease at the millennium. Neurology (2000) 55 1075-1081.
14. VAN DUIJN CM, DELASNERIE-LAUPRETRE N, MASULLO C et al.: Case-control study of risk factors of Creutzfeldt-Jakob disease in Europe during 1993-95. European Union (EU) Collaborative Study Group of Creutzfeldt-Jakob disease (CJD). Lancet (1998) 351:1081-1085.
15. WIENTJENS DP, DAVANIPOUR Z, HOFMAN A et al.: Risk factors for Creutzfeldt-Jakob disease: a reanalysis of case-control studies. Neurology (1996) 46:1287-1291.
16. BOBOWICK AR, BRODY JA, MATTHEWS MR, ROOS R, GAJDUSEK DC: Creutzfeldt-Jakob disease: a case-control study. Am. J. Epidemiol. (1973) 98:381-394.
17. DAVANIPOUR Z, ALTER M, SOBEL E, AL E: Creutzfeldt-Jakob disease: possible medical risk factors. Neurology (1985) 35 1483-1486.
18. KONDO K, KUROIWA Y: A case-control study of Creutzfeldt-Jakob disease: association with physical injuries. Ann. Neurol. (1982) 11:377-381.
19. XI YG, INGROSSO L, LADOGANA A, AL E: Amphotericin B treatment dissociates in vivo replication of the scrapie agent from PrP accumulation. Nature (1992) 356:598-601.
20. POCCHIARI M, SCHMITTINGER S, MASULLO C: Amphotericin B delay the incubation period of scrapie in intracerebrally inoculated hamsters. J. Gen. Virol. (1987) 68:219-223.
21. MCKENZIE D, KACZKOWSKI J, MARSH R, AIKEN J: Amphotericin B delays both scrapie agent replication and PrP-res accumulation in early infection. J. Virol. (1994) 68:7534-7536.
22. TAGLIAVINI F, MCARTHUR RA, CANCIANI B, AL E: Effectiveness of anthracycycline against experimental prion disease in Syrian hamsters. Science (1997) 276:1119-1122.
23. PRIOLA S, RAINES A, CAUGHEY WS: Porphyrin and phthalocyanine anti-scrapie compounds. Science (2000) 287:1503-1506.
24. CAUGHEY WS, RAYMOND LD, HORIUCHI M, CAUGHEY B: Inhibition of protease-resistant prion protein formation by porphyrins and phthalocyanines. Proc. Natl. Acad. Sci. USA (1998) 95 12117-12122.
25. CAUGHEY B, ERNST D, RACE R: Congo-red inhibition of scrapie-agent replication. J. Virol. (1993) 67:6270-6272.
26. CAUGHEY B, RACE R: Potent inhibition of scrapie-associated PrP accumulation by Congo red. J. Neurochem. (1992) 59 768-771.
27. INGROSSO L, LADOGANA A, POCCHIARI M: Congo red prolongs the incubation period in scrapie-infected hamsters. J. Virol. (1995) 69:506-508.
28. CAUGHEY B, RAYMOND G: Sulfated polyanion inhibition of scrapie-associated PrP accumulation in cultured cells. J. Virol. (1993) 67:643-650.
29. DIRINGER H, EHLERS B: Chemoprophylaxis of scrapie in mice. J. Gen. Virol. (1991) 72:457-460.
30. KIMBERLIN RH, WALKER CA: Suppression of scrapie infection in mice by heteropolyanion 23, dextran sulfate, and some other polyanions. Antimicrob. Agents Chemother. (1986) 30:409-413.
31. LADOGANA A, CASACCIA P, INGROSSO L, AL E: Sulphate polyanions prolong the incubation period of scrapie-infected hamsters. J. Gen. Virol. (1992) 73:661-665.
32. EHLERS B, DIRINGER H: Dextran sulphate 500 delays and prevents mouse scrapie by impairment of agent replication in spleen. J. Gen. Virol. (1984) 65:1325-1330.
33. MASULLO C, MACCHI G, XI YG, POCCHIARI M: Failure to ameliorate Creutzfeldt-Jakob disease with amphotericin B therapy. J. Infect. Dis. (1992) 165:784-785.
34. FARQUHAR C, DICKINSON A, BRUCE M: Prophylactic potential of pentosan polysulphate in transmissible spongiform encephalopathies. Lancet (1999) 353:117.
35. BROWN P: Drug therapy in human and experimental transmissible spongiform encephalopathy. Neurology (2002) 58:1720-1725.
36. SETHI S, LIPFORD G, WAGNER H, KRETZSCHMAR H: Postexposure prophylaxis against prion disease with a stimulator of innate origin. Lancet (2002) 360:229-230.
37. IVERSEN L: Amyloid diseases: small drugs lead the attack. Nature (2002) 417:231-233.
38. SOTO C, KASCSAK RJ, SABORIO GP et al.: Reversion of prion protein conformational changes by synthetic β-sheet breaker peptides. Lancet (2000) 355:192-197.
39. SOTO C, SIGURDSSON EM, MORELLI L, KUMAR RA, EM C, FRANGIONE B: β-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy. Nat. Med. (1998) 4:822-826.
40. CHABRY J, CAUGHEY B, CHESEBRO B: Specific inhibition of in vitro formation of protease-resistant prion protein by synthetic peptides. J. Biol. Chem. (1998) 273:13203-13207.
41. PERETZ D, WILLIAMSON RA, KANEKO K et al.: Antibodies inhibit prion propagation and clear cell cultures of prion infectivity. Nature (2001) 412:739-743.
42. ENARI M, FLECHSIG E, WEISSMANN C: Scrapie prion protein accumulation by scrapie-infected neuroblastoma cells abrogated by exposure to a prion protein antibody. Proc. Natl. Acad. Sci. USA (2001) 98:9295-9299.
43. HEPPNER FL, MUSAHL C, ARRIGHI I et aL: Prevention of scrapie pathogenesis by transgenic expression of anti-prion protein antibodies. Science (2001) 294:178-182.
44. WHITE AR, ENEVER P, TAYEBI M et al.: Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature (2003) 422:80-83.
45. SCHENK D, GAMES D, SEUBERT P: Potential treatment opportunities for Alzheimer's disease through inhibition of secretases and Ab immunization. J. Mol. Neurosci. (2001) 17:259-267.
46. SCHENK D, BARBOUR R, DUNN W et al.: Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature (1999) 400:173-177.
47. KORTH C, MAY BC, COHEN FE, PRUSINER SB: Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc. Natl. Acad. Sci. USA (2001) 98:9836-9841.
48. DOH-URA K, IWAKI T, CAUGHEY B: Lysosomotropic agents and cysteine protease inhibitors inhibit scrapie-associated prion protein accumulation. J. Virol. (2000) 74:4894-4897.
49. COLLINS JS, LEWIS V, BRAZIER M, HILL AF, FLETCHER A, MASTERS CL: Quinacrine does not prolong survival in a murine Creutzfeldt-Jakob disease model. Ann. Neurol. (2002) 52:503-506.
50. FORLONI G, IUSSICH S, AWAN T et al.: Tetracyclines affect prion infectivity. Proc. Natl. Acad. Sci. USA (2002) 99 10849-10854.